2021/06 - Philadelphia Business Journal
Century Therapeutics IPO climbs to more than $242M; stock rises over 30%Read more
The $242.65 million is the most raised in a local life sciences IPO since Passage Bio went public in March 2020.
2021/06 - Endpoints News
Another busy week for IPOs begins with an off-the shelf cell therapy player sniffing around unicorn statusRead more
A flurry of biotechs are expected to hit Nasdaq this week, with two companies, Ambrx Biopharma and Century Therapeutics, setting the terms for their public debuts, with expected raises at $126 million and $200 million, respectively.
2021/03 - BioSpace
Cell Therapy Company Raises $160 Million to Advance iPSC-Derived Therapies to ClinicRead more
Century Therapeutics received a $160 million infusion of cash to advance the company’s pipeline of induced pluripotent stem cell (iPSC)-derived cell therapies for cancer.
2021/03 - BioWorld
Century closes $160M series C round as first programs edge toward trialsRead more
Century Therapeutics Inc. raised $160 million in a series C round to progress its preclinical pipeline of allogeneic cell therapies for cancer, which are derived from induced pluripotent stem cells (iPSCs), and to expand its operational, laboratory and production facilities across several locations.
2021/02 - Endpoints News
Century Therapeutics boosts iPSC manufacturing space in New Jersey as part of company wide expansionRead more
It’s been a busy few years for Pennsylvania-based Century Therapeutics since it burst onto the scene with a $250M funding haul in summer 2019. Now, the biotech is scaling up its manufacturing capacity as part of a companywide footprint buildout.
2019/07 - HEALIO
Bayer among financial backers of startup Century Therapeutics’ cell-based immunotherapy platformRead more
Century Therapeutics was created by the investment firm Versant Ventures and has secured $250 million in total initial funding. The firm has partnered with Fujifilm Cellular Dynamics (FCDI) to license the induced pluripotent stem cells (iPSC) immune effector cell platform that will underlie Century’s investigational oncology therapies.
2019/07 - C&EN
Century Therapeutics launches to develop stem cell-derived, gene-edited cell therapies for cancerRead more
Century Therapeutics is the latest start-up to launch with plans to develop off-the-shelf cancer cell therapies, and it has gene editing tools, stem cell technology, and $250 million in financing to do it.
2019/07 - Scrip
Versant's Century Aims For Off-The-Shelf Cancer Cell TherapiesRead more
With Bayer’s venture arm providing $215m, Versant Ventures’ Century Therapeutics emerges with $250m and a plan to develop allogeneic stem cell therapies for various cancers, including solid tumors.
2019/07 - BioPharma Dive
Bayer backs cell therapy startup with $215M in fundingRead more
The financing, which was announced Monday, comes via the German pharma's venture investment arm Leaps by Bayer. Versant Ventures, Century's creator, and Fujifilm Cellular Dynamics will add another $35 million to bring Century's funding to $250 million.
2019/07 - Fierce Biotech
Bayer powers Versant cell therapy startup to $250M roundRead more
Versant Ventures’ Century Therapeutics has exited stealth with $250 million to take allogeneic cell therapies into the clinic. Bayer’s VC wing led the investment with the support of Versant and Fujifilm Cellular Dynamics (FCDI).
2019/06 - WSJ
Biotech Startup Century Therapeutics Lands $250 Million in Venture FinancingRead more
Company is developing cellular therapy treatments for cancer. Corporate and venture-capital investors are funneling $250 million into startup Century Therapeutics LLC to finance an effort to cure cancers through a new type of cellular therapy.
2019/07 - Endpoints News
Bayer, Versant back a $250M cell therapy startup on a quest to create off-the-shelf immuno-oncology therapiesRead more
Look out Fate Therapeutics — Versant Ventures’ Century Therapeutics is lurking in the burgeoning field of off-the-shelf cell therapeutics that offer the promise of quicker, cheaper and potent cancer treatments. The Philadelphia-based biotech unveiled on Monday a meaty $250 million round of financing — led by Bayer’s venture arm — after Versant spawned it in 2018 to develop induced pluripotent stem cells (iPSC)-derived products to fight cancer.
2019/07 - BIOCENTURY
Versant, Bayer bet big on iPS cells to tackle price, efficacy of CAR therapiesRead more
Looking to tap allogeneic iPS cells to address the shortcomings of CAR cell therapies, Bayer and Versant Ventures launched Century Therapeutics on Monday with $250 million in funding.